| temozolomide / Generic mfg. |
ChiCTR2000036967: Study on differences in intestinal flora of patients with relapsed/refractory neuroblastoma in children with different responses to irinotecan combined with temozolomide |
|
|
| Recruiting | N/A | 150 | | Irinotecan combined with temozolomide ;Nil | Xinhua Hospital affiliated to Shanghai Jiao Tong University School Of Medicine; Xinhua Hospital affiliated to Shanghai Jiao Tong University School Of Medicine, Hospital Development Center | Recurrent/refractory neuroblastoma in children | | | | |
ChiCTR-TRC-11001798: Randomized phase II trial comparing temozolomide plus cisplatin, high-dose interferon alpha-2b or observation in resectable mucosal melanoma patients |
|
|
| Completed | N/A | 189 | | observation ;inteferon ;Chemotherapy | Peking University Cancer Hospital and Institute; Peking University Cancer Hospital and Institute, the National Natural Science Foundation of China (30973483, 81172196, 81102068) | melenoma | | | | |
NCT01837212: Veliparib and Temozolomide For Compassionate Use in Patients With Primary Refractory Ovarian Cancer |
|
|
| Enrolling by invitation | N/A | 3 | US | veliparib, ABT-888, temozolomide, SCH 52365, Temodal, Temodar, TMZ | New Mexico Cancer Care Alliance, National Cancer Institute (NCI) | Recurrent Ovarian Epithelial Cancer | 12/14 | 12/15 | | |
ChiCTR-OOC-15006736: Phase 0 clinical study of very low single-dose Temozolomide Capsule to healthy Chinese male volunteers |
|
|
| Recruiting | N/A | 14 | | 3mg Temozolomide Capsule single-dose | Beijing Shijitan Hospital Capital Medical University; Beijing Shijitan Hospital Capital Medical University, Research Project of Beijing Municipal Science and Technology Commission | pilot study of micro dose | | | | |
ChiCTR-IPR-15006066: Clinical research of chemotherapy consisted of temozolomide with concomitant sodium valproate and nicardipine for Glioma |
|
|
| Not yet recruiting | N/A | 40 | | TMZ ;TMZ+Nicardipine+Sodium Valproate | Department of Neurosurgery, The Second Affiliated Hospital of Suzhou University; The Second Affiliated Hospital of Suzhou University, Chinese Anti Cancer Association Fund | glioma | | | | |
| No Longer Available | N/A | | RoW | pembrolizumab, MK-3475 | Center Trials & Treatment | Melanoma (Skin), Melanoma Recurrent, Glioblastoma Multiforme, Glioblastoma by Gene Expression Profile, Glioma of Brain | | | | |
| Not yet recruiting | N/A | 30 | | ultra-low dose Bevacizumab plus Temozolomide | Hebei Yanda Hospital; Hebei Yanda Hospital, Supported by Hebei Yanda Hospital | Recurrent High-grade Glioma | | | | |
| Not yet recruiting | N/A | 1000 | | N/A | Xiangya Hospital, Central South University; Xiangya Hospital, Central South University, Natural Science Foundation of China | glioma | | | | |
Gamma-GBM, NCT03055208: Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma |
|
|
| Suspended | N/A | 50 | Europe | gamma knife radiosurgery (15 Gy to 50% isodose) | Universitätsmedizin Mannheim | Glioblastoma | 03/20 | 05/23 | | |
ChiCTR1800016291: Radiotherapy combined with temozolomide (Tai dao) in the treatment of brain metastasis of non-small cell lung cancer: a multicenter randomized controlled trial |
|
|
| Not yet recruiting | N/A | 50 | | Temozolomide combined with whole brain radiation therapy ;Whole brain radiation therapy | The first hospital of China Medical University; The first hospital of China Medical University, The SCI fund of the department of radiotherapy of the first hospital of China Medical University | Lung cancer with brain metastasis | | | | |
ChiCTR1800019217: Mechanism and clinical study of lncRNA FOXD1-AS1 regulating temozolomide resistance |
|
|
| Recruiting | N/A | 100 | | Temozolomide ;Temozolomide | The First Hospital of Hunan University of Chinese Medicine; The First Hospital of Hunan University of Chinese Medicine, National Natural Youth Project Fund | glioma | | | | |
NCT03642080: MRI Predictors of Response to Tumor Treating Fields |
|
|
| Recruiting | N/A | 48 | US | | New York Presbyterian Brooklyn Methodist Hospital | Glioblastoma Multiforme | 09/21 | 12/23 | | |
NCT03278249: Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma |
|
|
| Active, not recruiting | N/A | 11 | US | Modified Atkins Ketogenic Diet | University of Cincinnati | Glioblastoma | 12/21 | 01/22 | | |
| Not yet recruiting | N/A | 30 | RoW | TTFields | Zhongnan Hospital | Glioma, Glioblastoma | 12/21 | 07/22 | | |
ChiCTR2000034017: Study on the clinical benefits of reoperation in patients with recurrent glioblastoma |
|
|
| Not yet recruiting | N/A | 180 | | Maximum range of brain tumor resection +/ chemotherapy (temozolomide/bevacizumab)+/ radiotherapy + adjuvant therapy ;Maximum range of brain tumor resection +adjuvant therapy ;Chemotherapy (temozolomide/bevacizumab)+/ radiotherapy + adjuvant therapy ;Chemotherapy (temozolomide/bevacizumab)+ adjuvant therapy | Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University, Investigator sponsored | Glioblastoma | | | | |
ChiCTR2100047925: The role and mechanism of pericyte in temozolomide resistance of glioma |
|
|
| Not yet recruiting | N/A | 99 | | None | the First Affiliated Hospital of Army Medical University, PLA; 30 Gaotanyan Main Street, Shapingba District, National Natural Science Foundation of China (81772660) | Glioma | | | | |
MM-Predict, NCT03526822: Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features. |
|
|
| Recruiting | N/A | 100 | Europe | Blood sample, Tumor sample | Assistance Publique Hopitaux De Marseille | Brain Tumor | 07/27 | 07/27 | | |
ChiCTR2000033714: The mechanism of brain glioma and the research plan of anti-glial tumor drugs |
|
|
| Recruiting | N/A | 72 | | temozolomide ;Low dose ;High dose ;temozolomide ;Low dose ;High dose ;temozolomide ;Low dose ;High dose; temozolomide ;Low dose ;High dose | Department of Experimental Zoology, Kunming Medical University; Department of Experimental Zoology, Kunming Medical University, National Natural Science Foundation | Glioma | | | | |
ChiCTR2100054482: Efficacy of high-dose cytarabine combined with temozolomide in the treatment of refractory/relapsed primary central nervous system lymphoma: an analysis based on medical records |
|
|
| Completed | N/A | 40 | | None | Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Shanghai Shenkang Clinical Innovation Project (SHDC12020112) | primary central nervous system lymphoma | | | | |
NCT04488783: Potentiation of Chemotherapy in Brain Tumors by Zinc |
|
|
| Recruiting | N/A | 30 | RoW | zinc and ascorbate | Sheba Medical Center | Newly Diagnosed Glioblastoma Who Underwent at Least Partial Resection of the Tumor Surgically | 07/22 | 12/22 | | |
IBCNG, NCT04856852: Iodine-125 Brachytherapy Together With Chemotherapy in Patients With Newly Diagnosed Glioblastoma |
|
|
| Not yet recruiting | N/A | 84 | NA | Iodine-125+Chemotherapy, Iodine-125+Temozolomide, Surgical resection+Radiochemotherapy, Surgical resection+Radiotherapy+Temozolomide | The Affiliated Hospital of Qingdao University | Glioblastoma | 08/22 | 08/23 | | |
NCT04446416: Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients |
|
|
| Completed | N/A | 6 | RoW | NaviFUS System, Bevacizumab, Avastin | NaviFUS Corporation, Chang Gung Memorial Hospital | Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor, Neoplasms, Neoplasms, Nerve Tissue | 09/22 | 08/23 | | |
NCT02751138: Determination of Immune Phenotype in Glioblastoma Patients |
|
|
| Completed | N/A | 100 | Europe | Surgery | University of Ulm | Glioblastoma Multiforme | 12/22 | 01/23 | | |
| Completed | N/A | 18 | RoW | genetic characteristic | Beijing Sanbo Brain Hospital | Glioblastoma | 12/22 | 06/23 | | |
ChiCTR2000028768: Clinical research for the treatment of IDH wild-type glioblastoma by conbination of simultaneous integrated boosts radiotherapy and concurrent adjuvant temozolomide chemotherapy |
|
|
| Not yet recruiting | N/A | 128 | | simultaneous integrated boosts radiotherapy PTV1 60Gy/30F; PTV2 66Gy/30F and concurrent adjuvant temozolomide chemotherapy ;Standard radiotherapy PTV 60Gy/30F and concurrent adjuvant temozolomide chemotherapy | Department of Oncology, Xiangya Hospital, Central South University; Xiangya Hospital, Research fund project of hunan development and reform commission | Glioblastoma | | | | |
ChiCTR2100042230: A study of apatinib combined with dose-intensive temozolomide for the treatment of first-recurrence high-grade glioma |
|
|
| Recruiting | N/A | 37 | | Temozolomide 100mg/mm2 Po, take for 7 days and stop for 7 days; Apatinib 250mg, PO, QD | Shanxi Provincial People's Hospital; Shanxi Provincial People's Hospital, self-raised | Glioma | | | | |
RECSUR, NCT06283927: The -study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) |
|
|
| Recruiting | N/A | 464 | Europe, US | Re-resection, Temozolomide, Lomustine, Re-irradiation, Experimental therapy, Immunotherapy, Oncolytic virotherapy, Best supportive care | Jasper Gerritsen, Haaglanden Medical Centre, Universitaire Ziekenhuizen KU Leuven, University Hospital Heidelberg, Technical University of Munich, Insel Gruppe AG, University Hospital Bern, Massachusetts General Hospital, University of California, San Francisco | Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, Recurrent Glioblastoma, Astrocytoma, Malignant, Astrocytoma of Brain | 01/27 | 01/28 | | |
SAFE, NCT03861299: The -Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients. |
|
|
| Recruiting | N/A | 246 | Europe | Awake craniotomy, Intraoperative stimulation monitoring with (sub)cortical electrostimulation, Intraoperative brain mapping with (sub)cortical electrostimulation, Craniotomy under general anesthesia | Jasper Gerritsen, Elisabeth-TweeSteden Ziekenhuis, University Medical Center Groningen, Medical Center Haaglanden, University Hospital, Ghent | Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Astrocytoma, Grade IV, Brain Tumor, Brain Cancer, Brain Neoplasms | 09/26 | 09/27 | | |
NCT06346821: Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data |
|
|
| Recruiting | N/A | 200 | RoW | Optune® (Tumor Treating Fields) | Sichuan University | Glioblastoma Multiforme | 04/24 | 05/24 | | |
NCT06140875: Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF) |
|
|
| Recruiting | N/A | 26 | Europe | Radiofrequency electromagnetic field treatment, mEHT, capacitive hyperthermia, electrohyperthermia | Charite University, Berlin, Germany | Glioblastoma | 05/29 | 05/29 | | |
FARINET, NCT06356467: Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs |
|
|
| Active, not recruiting | N/A | 450 | Europe | | IRCCS San Raffaele | Neuroendocrine Tumors, GEP-NET | 12/24 | 12/24 | | |
NCT03616860: Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma |
|
|
| Completed | N/A | 14 | Canada | Focused Ultrasound (FUS) BBB Disruption, Exablate Neuro | InSightec | Glioblastoma | 12/23 | 12/23 | | |
NCT04530006: Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma |
|
|
| Recruiting | N/A | 20 | Canada | Amantadine Hydrochloride | CancerCare Manitoba, University of Manitoba, The Metabolomics Innovation Centre, BioMark Diagnostics Inc., Canadian Institutes of Health Research (CIHR) | Glioblastoma Multiforme | 12/24 | 08/25 | | |
ChiCTR2000034285: To evaluate the safety and efficacy of wearable glioma electric field therapy combined with temozolomide in the treatment of recurrent glioblastoma (GBM): a randomized, controlled, open-label, multicenter trial. |
|
|
| Not yet recruiting | N/A | 300 | | PETF + Temozolomide ;Temozolomide | Beijing Tiantan Hospital, Capital Medical University; Hebei Puni Medical Technology Co., Ltd., Hebei Puni Medical Technology Co., Ltd. | Recurrent GBM | | | | |
ChiCTR2200066575: Individualized treatment of recurrent/refractory primary CNS lymphoma based on cerebrospinal fluid proteomics |
|
|
| Not yet recruiting | N/A | 60 | | One course of total cranial radiotherapy ;High-dose cytarabine (3g/m^2d1-2) with zebratinib (160 mgbidpo) or temozolomide (150 mg/m^2d1-5) was administered for 8 courses | Huashan Hospital, Fudan University ; Huashan Hospital, Fudan University, Shanghai Shenkang Development Center | Primary central nervous system lymphoma (PCNSL) | | | | |
NCT06176066: PH Sensitive MRI Based Resections of Glioblastoma |
|
|
| Not yet recruiting | N/A | 60 | US | CEST PH MRI based resection of glioblastoma | University of California, Los Angeles | Glioblastoma | 01/27 | 01/29 | | |
| Recruiting | N/A | 100 | Europe | NanoTherm therapy, Cyclic hyperthermia, Glioma Resection, Surgical removal of Glioma tumor, radiotherapy according to Stupp protocol, chemotherapy according to Stupp protocol, temozolomide | Poznan University of Medical Sciences, MagForce USA | Glioblastoma Multiforme | 02/27 | 09/27 | | |
ChiCTR2200056169: A prospective, single-arm clinical study of antiangiogenic drugs combined with temozolomide in the treatment of postoperative recurrent Glioblastoma multiforme under the guidance of molecular pathology |
|
|
| Not yet recruiting | N/A | 60 | | Anlotinib ;Temozolomide | The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, No | Glioblastoma | | | | |
NCT06215495: A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial |
|
|
| Recruiting | N/A | 88 | RoW | reduced target volume, EORTC (European organisation for research and treatment of cancer) target volume | Zhujiang Hospital | Radiation Toxicity, MRI Simulated Positioning, High Grade Glioma, Progression-free Survival, Overall Survival | 05/27 | 06/27 | | |
NCT06381726: Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life |
|
|
| Recruiting | N/A | 400 | Europe | Resting State Functional Magnetic Resonance Imaging (rs-fMRI), Up-front Motor Rehabilitation, Up-front Chemotherapy | University of Milan, University of Turin, Italy | Glioma, Glioma, Malignant | 02/28 | 02/28 | | |
NCT01535911: Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors |
|
|
| Active, not recruiting | N/A | 16 | US | Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy), Ketogenic diet | Michigan State University, Sparrow Health System | Glioblastoma | 06/26 | 06/26 | | |
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM |
|
|
| Active, not recruiting | N/A | 950 | Europe, Canada, Japan, US, RoW | Optune® | NovoCure GmbH | Glioblastoma Multiforme | 08/24 | 08/26 | | |
NCT04730869: Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma |
|
|
| Recruiting | N/A | 22 | RoW | Standard Treatment Plus Metabolic Therapy Program | Waikato Hospital, Wellington Hospital | Glioblastoma | 12/24 | 12/24 | | |
ChiCTR2100053385: A study evaluating the conversion therapy of surufatinib in combination with chemotherapy in patients with unresectable pancreatic neuroendocrine tumor (PNET) |
|
|
| Recruiting | N/A | 24 | | Surufatinib+Capecitabine + Temozolomide ;Surufatinib+Etoposide+cisplatin | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Hutchison Whampoa Pharmaceuticals (Shanghai) Co., Ltd. | pancreatic neuroendocrine tumor | | | | |
ChiCTR2100047776: Clinical study on the role of secretory autophagy protein HMGB1 in the treatment resistance of temozolomide in glioblastoma |
|
|
| Not yet recruiting | N/A | 39 | | No | the First Affiliated Hospital of Army Medical University, PLA; The First Affiliated Hospital of Army Medical University, PLA, the National Natural Science Foundation of China (81874087) | glioblastoma | | | | |
ChiCTR2100047049: Evaluate the efficacy and safety of Tumor Eletric Field Therapy System in the treatment of newly diagnosed supratentorial glioblastoma |
|
|
| Recruiting | N/A | 411 | | Tumor Treating Fields + Temozolomide ;Temozolomide | Beijing Tiantan Hospital, Capital Medical University; Hunan An Tai Kang Cheng Biotechnology Co., Ltd, Hunan An Tai Kang Cheng Biotechnology Co., Ltd | Glioblastoma Multiforme | | | | |
ChiCTR2000034706: Prospective, multicenter, open, randomized, parallel controlled trial for tumor treating fields (EFE-G100) combined with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma |
|
|
| Not yet recruiting | N/A | 330 | | Tumor Treating Fields+PETF + Temozolomide ;Temozolomide | Huashan Hospital Affiliated to Fudan University; Jiangsu Healthy life Innovation Medical Technology Co., Ltd., Jiangsu Healthy life Innovation Medical Technology Co., Ltd. | Glioblastoma multiforme | | | | |
| Recruiting | N/A | 20 | Canada | | Ottawa Hospital Research Institute | Glioblastoma, IDH-wildtype | 07/25 | 09/29 | | |
NCT02613988: Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas |
|
|
| Recruiting | N/A | 100 | RoW | 3 Tesla magnetic resonance imaging, Chemical exchange saturation transfer MRI, Diffusion weighted MRI, Dynamic susceptibility contrast MRI | Asan Medical Center | Adult Glioblastoma | 12/25 | 12/25 | | |
NCT05512325: Study on Gene Evolution in Glioma Under Stress Therapy |
|
|
| Not yet recruiting | N/A | 100 | RoW | Gene evolution and molecular response under Bevacizumab treatment | Henan Provincial People's Hospital | Genetic Change | 12/25 | 12/26 | | |
| Recruiting | N/A | 90 | Europe | Supramarginal resection, Conventional surgery | St. Olavs Hospital, Odense University Hospital, Sahlgrenska University Hospital, Sweden, Turku University Hospital, Karolinska University Hospital, Norwegian University of Science and Technology, University Hospital, Linkoeping, Uppsala University Hospital, University Hospital, Umeå, Skane University Hospital, Haukeland University Hospital, Ullevaal University Hospital, Rikshospitalet University Hospital, University Hospital of North Norway, Tampere University Hospital, Helsinki University Central Hospital, Kuopio University Hospital, Oulu University Hospital, Medical University of Vienna, Paracelsus Medical University | Glioblastoma | 03/26 | 03/30 | | |
ChiCTR2100045593: A multicenter, open, prospective, randomized controlled clinical trial of neoadjuvant immunotherapy, immunotherapy combined with concurrent chemoradiotherapy and adjuvant therapy for postoperative residual high-grade glioma |
|
|
| Recruiting | N/A | 50 | China | Teriprizumab neoadjuvant immunotherapy + temozolomide capsules combined with IMRT concurrent chemotherapy + postoperative adjuvant radiotherapy + oral temozolomide capsules adjuvant chemotherapy one month after the end of radiotherapy ;Temozolomide capsules combined with IMRT concurrent chemotherapy + postoperative adjuvant radiotherapy + oral temozolomide capsules adjuvant chemotherapy one month after the end of radiotherapy | The Affiliated Hospital of Guizhou Medical University/The Affiliated Cancer Hospital of Guizhou Medical University ; The Affiliated Cancer Hospital of Guizhou Medical University, Fund Project Support | Glioma | | | | |
NCT06113705: Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study. |
|
|
| Not yet recruiting | N/A | 75 | Europe | 18F-GE-180 PET, Advanced MRI, Collection of hematopoietic stem cells, Blood withdrawal, Collection of Cancer Stem Cells | Istituto Clinico Humanitas, Mediolanum Cardio Research | Glioblastoma | 12/26 | 12/26 | | |
NCT05695976: GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM |
|
|
| Recruiting | N/A | 100 | US | | Duke University, Personalis Inc. | Glioblastoma, Glioma, Malignant | 01/29 | 01/29 | | |
